Research programme: small molecule WRD5/MLL1 inhibitors - Biolexis Therapeutics

Alternative Names: BLX-2000

Latest Information Update: 30 Jun 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biolexis Therapeutics
Class Small molecules
Mechanism of Action Myeloid lymphoid leukemia protein inhibitors; WDR5 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

20 Jun 2023 small molecule WRD5/MLL1 inhibitors - Biolexis Therapeutics is available for licensing as of 20 Jun 2023. https://biolexistx.com/#pipeline (Biolexis Therapeutics website, June 2023)
20 Jun 2023 Preclinical trials in Unspecified in USA (unspecified route) before June 2023 (Biolexis Therapeutics pipeline, June 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com